IDEAYA Biosciences Quarterly Balance Sheets Chart
Quarterly
|
Annual
IDEAYA Biosciences Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||||||||||
| current assets | |||||||||||||||||||||||||
| cash and cash equivalents | 114,645,000 | 129,996,000 | 84,378,000 | 400,283,000 | 183,049,000 | 108,345,000 | 157,018,000 | 151,850,000 | 102,843,000 | 67,237,000 | 68,632,000 | 101,954,000 | 49,106,000 | 55,291,000 | 92,046,000 | 108,428,000 | 90,427,000 | 136,752,000 | 72,037,000 | 81,238,000 | 147,543,000 | 35,462,000 | 34,067,000 | 38,848,000 | 88,115,000 |
| short-term marketable securities | 555,093,000 | 562,512,000 | 591,941,000 | 519,746,000 | 518,609,000 | 590,427,000 | 368,096,000 | 316,901,000 | 390,873,000 | 272,233,000 | 296,197,000 | 284,290,000 | 219,514,000 | 197,308,000 | 154,724,000 | 156,123,000 | 183,749,000 | 165,569,000 | 211,548,000 | 197,445,000 | 22,871,000 | 52,401,000 | 64,889,000 | 70,508,000 | 32,048,000 |
| prepaid expenses and other current assets | 15,864,000 | 15,364,000 | 13,391,000 | 12,165,000 | 11,520,000 | 10,566,000 | 7,500,000 | 6,728,000 | 7,912,000 | 4,020,000 | 5,414,000 | 3,744,000 | 3,281,000 | 2,753,000 | 3,123,000 | 3,394,000 | 4,288,000 | 2,915,000 | 3,143,000 | 2,654,000 | 3,536,000 | 1,601,000 | 2,698,000 | 2,805,000 | 2,469,000 |
| total current assets | 685,602,000 | 707,872,000 | 689,713,000 | 932,214,000 | 713,179,000 | 709,353,000 | 532,632,000 | 482,182,000 | 501,788,000 | 343,958,000 | 370,454,000 | 393,437,000 | 272,189,000 | 256,049,000 | 250,996,000 | 268,963,000 | 279,789,000 | 308,158,000 | 288,605,000 | 281,337,000 | 173,950,000 | 89,464,000 | 101,654,000 | 112,161,000 | 122,632,000 |
| restricted cash | 805,000 | 805,000 | 805,000 | 911,000 | 911,000 | 757,000 | 757,000 | 722,000 | 722,000 | 106,000 | 106,000 | 106,000 | 106,000 | 106,000 | 106,000 | 106,000 | 106,000 | 106,000 | 106,000 | 106,000 | 106,000 | 106,000 | 106,000 | 106,000 | 106,000 |
| long-term marketable securities | 322,131,000 | 358,665,000 | 405,832,000 | 280,128,000 | 251,071,000 | 242,636,000 | 107,492,000 | 42,394,000 | 16,377,000 | 11,740,000 | 8,317,000 | 7,691,000 | 55,171,000 | 93,628,000 | 121,293,000 | 121,217,000 | 38,254,000 | 8,080,000 | 10,158,000 | 1,545,000 | 3,040,000 | 1,526,000 | |||
| property and equipment | 8,819,000 | 8,871,000 | 8,966,000 | 8,235,000 | 7,122,000 | 6,909,000 | 6,164,000 | 6,192,000 | 6,829,000 | 6,716,000 | 6,509,000 | 6,679,000 | 7,163,000 | 5,274,000 | 4,763,000 | 4,707,000 | 4,898,000 | 4,755,000 | 4,271,000 | 4,095,000 | 4,289,000 | 4,337,000 | 4,642,000 | 4,767,000 | 5,050,000 |
| right-of-use assets | 23,913,000 | 24,428,000 | 18,775,000 | 18,385,000 | 1,305,000 | 1,780,000 | 2,246,000 | 1,347,000 | 1,733,000 | 2,112,000 | 2,484,000 | 2,848,000 | 3,204,000 | 3,554,000 | 3,898,000 | 4,234,000 | 4,563,000 | 4,887,000 | 5,205,000 | 5,515,000 | 4,594,000 | 4,828,000 | 5,057,000 | 5,279,000 | 5,545,000 |
| total assets | 1,041,270,000 | 1,100,641,000 | 1,124,091,000 | 1,239,873,000 | 973,663,000 | 961,527,000 | 649,316,000 | 532,942,000 | 527,557,000 | 364,746,000 | 387,969,000 | 410,907,000 | 338,007,000 | 358,867,000 | 381,347,000 | 399,444,000 | 328,401,000 | 326,097,000 | 298,269,000 | 301,384,000 | 184,510,000 | 101,791,000 | 113,001,000 | 122,331,000 | 133,358,000 |
| liabilities and stockholders’ equity | |||||||||||||||||||||||||
| current liabilities | |||||||||||||||||||||||||
| accounts payable | 17,270,000 | 17,631,000 | 15,421,000 | 12,567,000 | 15,886,000 | 6,290,000 | 6,598,000 | 5,169,000 | 5,868,000 | 4,376,000 | 4,280,000 | 3,645,000 | 4,227,000 | 3,364,000 | 2,100,000 | 2,152,000 | 2,108,000 | 1,281,000 | 953,000 | 1,405,000 | 952,000 | 684,000 | 709,000 | 763,000 | 1,080,000 |
| accrued liabilities | 37,750,000 | 32,907,000 | 30,352,000 | 28,092,000 | 24,250,000 | 17,519,000 | 18,756,000 | 16,188,000 | 14,690,000 | 17,274,000 | 16,999,000 | 16,988,000 | 16,230,000 | 12,628,000 | 12,320,000 | 11,892,000 | 9,910,000 | 7,756,000 | 8,516,000 | 6,390,000 | 5,223,000 | 5,429,000 | 5,023,000 | 3,992,000 | 4,077,000 |
| operating lease liabilities, current | 318,000 | 308,000 | 298,000 | 606,000 | 1,151,000 | 1,747,000 | 1,871,000 | 1,699,000 | 1,540,000 | ||||||||||||||||
| total current liabilities | 55,338,000 | 50,846,000 | 46,071,000 | 40,659,000 | 40,742,000 | 24,960,000 | 27,101,000 | 24,893,000 | 25,337,000 | 29,820,000 | 31,718,000 | 32,727,000 | 58,089,000 | 56,957,000 | 45,159,000 | 38,637,000 | 35,771,000 | 36,129,000 | 38,640,000 | 54,173,000 | 7,426,000 | 7,346,000 | 6,940,000 | 5,947,000 | 6,473,000 |
| long-term operating lease liabilities | 26,279,000 | 25,660,000 | 18,873,000 | 18,796,000 | 1,263,000 | 1,256,000 | 1,125,000 | 611,000 | 1,116,000 | 1,611,000 | 2,097,000 | 2,572,000 | 3,031,000 | 3,482,000 | 5,183,000 | ||||||||||
| total liabilities | 81,617,000 | 76,506,000 | 64,944,000 | 59,455,000 | 42,005,000 | 26,216,000 | 28,226,000 | 24,893,000 | 25,948,000 | 30,936,000 | 38,514,000 | 42,138,000 | 68,686,000 | 70,200,000 | 79,833,000 | 81,815,000 | 88,141,000 | 92,971,000 | 99,995,000 | 105,955,000 | 12,452,000 | 12,688,000 | 12,601,000 | 11,925,000 | 12,750,000 |
| commitments and contingencies | |||||||||||||||||||||||||
| stockholders’ equity | |||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of june 30, 2025 and december 31, 2024; no shares issued and outstanding as of june 30, 2025 and december 31, 2024 | |||||||||||||||||||||||||
| common stock | 9,000 | 9,000 | 9,000 | 9,000 | 8,000 | 7,000 | 7,000 | 6,000 | 6,000 | 5,000 | 5,000 | 5,000 | 4,000 | 4,000 | 4,000 | 4,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 2,000 | 2,000 | 2,000 | 2,000 |
| additional paid-in capital | 1,730,633,000 | 1,717,560,000 | 1,681,167,000 | 1,669,102,000 | 1,373,774,000 | 1,324,163,000 | 968,885,000 | 823,202,000 | 789,751,000 | 594,253,000 | 587,724,000 | 583,968,000 | 485,763,000 | 482,228,000 | 478,970,000 | 476,211,000 | 387,215,000 | 369,130,000 | 325,250,000 | 317,242,000 | 288,923,000 | 193,635,000 | 192,824,000 | 192,036,000 | 191,310,000 |
| accumulated other comprehensive income | 1,521,000 | 1,585,000 | 812,000 | 3,836,000 | -1,416,000 | -923,000 | 562,000 | -712,000 | -50,000 | -4,000 | 7,000 | 35,000 | 57,000 | 65,000 | 78,000 | 37,000 | |||||||||
| accumulated deficit | -772,510,000 | -695,019,000 | -622,841,000 | -492,529,000 | -440,708,000 | -387,936,000 | -348,364,000 | -314,409,000 | -286,969,000 | -259,043,000 | -235,403,000 | -211,202,000 | -212,817,000 | -190,761,000 | -176,748,000 | -158,536,000 | -146,954,000 | -136,007,000 | -126,986,000 | -121,851,000 | -116,925,000 | -104,534,000 | -92,491,000 | -81,710,000 | -70,741,000 |
| total stockholders’ equity | 959,653,000 | 1,024,135,000 | 1,059,147,000 | 1,180,418,000 | 931,658,000 | 935,311,000 | 621,090,000 | 508,049,000 | 501,609,000 | 333,810,000 | 349,455,000 | 368,769,000 | 269,321,000 | 288,667,000 | 301,514,000 | 317,629,000 | 240,260,000 | 233,126,000 | 198,274,000 | 195,429,000 | 172,058,000 | 89,103,000 | 100,400,000 | 110,406,000 | 120,608,000 |
| total liabilities and stockholders’ equity | 1,041,270,000 | 1,100,641,000 | 1,124,091,000 | 1,239,873,000 | 973,663,000 | 961,527,000 | 649,316,000 | 532,942,000 | 527,557,000 | 364,746,000 | 387,969,000 | 410,907,000 | 338,007,000 | 358,867,000 | 381,347,000 | 399,444,000 | 328,401,000 | 326,097,000 | 298,269,000 | 301,384,000 | 184,510,000 | 101,791,000 | |||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of march 31, 2025 and december 31, 2024; no shares issued and outstanding as of march 31, 2025 and december 31, 2024 | |||||||||||||||||||||||||
| accounts receivable | 3,000 | 20,000 | 1,000 | 15,000 | 18,000 | 6,703,000 | 160,000 | 468,000 | 211,000 | 3,449,000 | 288,000 | 697,000 | 1,103,000 | 1,018,000 | 1,325,000 | 2,922,000 | 1,877,000 | ||||||||
| other non-current assets | 75,000 | 92,000 | 25,000 | 105,000 | 108,000 | 114,000 | 99,000 | 146,000 | 174,000 | 256,000 | 291,000 | 217,000 | 791,000 | 111,000 | 82,000 | 173,000 | 26,000 | 16,000 | 16,000 | 18,000 | 25,000 | ||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of december 31, 2024 and december 31, 2023; no shares issued and outstanding as of december 31, 2024 and december 31, 2023 | |||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of september 30, 2024 and december 31, 2023; no shares issued and outstanding as of september 30, 2024 and december 31, 2023 | |||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of june 30, 2024 and december 31, 2023; no shares issued and outstanding as of june 30, 2024 and december 31, 2023 | |||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of march 31, 2024 and december 31, 2023; no shares issued and outstanding as of march 31, 2024 and december 31, 2023 | |||||||||||||||||||||||||
| contract liability | 1,439,000 | 2,818,000 | 6,255,000 | 8,568,000 | 10,267,000 | 35,849,000 | 39,224,000 | 29,040,000 | 22,935,000 | 22,132,000 | 25,508,000 | 27,613,000 | 44,847,000 | ||||||||||||
| long-term contract liability | 5,185,000 | 7,314,000 | 8,025,000 | 10,212,000 | 31,192,000 | 39,248,000 | 48,008,000 | 52,063,000 | 56,160,000 | 46,186,000 | |||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of december 31, 2023 and december 31, 2022; no shares issued and outstanding as of december 31, 2023 and december 31, 2022 | |||||||||||||||||||||||||
| operating lease liabilities - current | 2,097,000 | 1,961,000 | 1,915,000 | 1,827,000 | 1,783,000 | 1,741,000 | |||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of september 30, 2023 and december 31, 2022; no shares issued and outstanding as of september 30, 2023 and december 31, 2022 | |||||||||||||||||||||||||
| accumulated other comprehensive loss | -750,000 | -1,179,000 | -1,405,000 | -2,871,000 | -4,002,000 | -3,629,000 | -2,804,000 | ||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of june 30, 2023 and december 31, 2022; no shares issued and outstanding as of june 30, 2023 and december 31, 2022 | |||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of march 31, 2023 and december 31, 2022; no shares issued and outstanding as of march 31, 2023 and december 31, 2022 | |||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of december 31, 2022 and december 31, 2021; no shares issued and outstanding as of december 31, 2022 and december 31, 2021 | |||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of september 30, 2022 and december 31, 2021; no shares issued and outstanding as of september 30, 2022 and december 31, 2021 | |||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of june 30, 2022 and december 31, 2021; no shares issued and outstanding as of june 30, 2022 and december 31, 2021 | |||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of march 31, 2022 and december 31, 2021; no shares issued and outstanding as of march 31, 2022 and december 31, 2021 | |||||||||||||||||||||||||
| other current liabilities | 3,000 | 6,000 | 18,000 | 29,000 | 45,000 | 57,000 | 63,000 | 76,000 | 89,000 | ||||||||||||||||
| other non-current liabilities | 6,000 | 6,000 | 6,000 | 12,000 | 12,000 | 16,000 | 21,000 | 34,000 | 52,000 | 60,000 | |||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of december 31, 2021 and december 31, 2020; no shares issued and outstanding as of december 31, 2021 and december 31, 2020 | |||||||||||||||||||||||||
| lease liabilities | 1,658,000 | 1,618,000 | 1,578,000 | 1,502,000 | 1,206,000 | 1,176,000 | 1,145,000 | 1,116,000 | 1,227,000 | ||||||||||||||||
| long-term lease liabilities | 3,924,000 | 4,356,000 | 4,773,000 | 5,584,000 | 5,010,000 | 5,321,000 | 5,627,000 | 5,926,000 | 6,217,000 | ||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of september 30, 2021 and december 31, 2020; no shares issued and outstanding as of september 30, 2021 and december 31, 2020 | |||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of june 30, 2021 and december 31, 2020; no shares issued and outstanding as of june 30, 2021 and december 31, 2020 | |||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of march 31,2021 and december 31, 2020; no shares issued and outstanding as of march 31, 2021 and december 31, 2020 | |||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of december 31, 2020 and december 31, 2019; no shares issued and outstanding as of december 31, 2020 and december 31, 2019 | |||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of september 30, 2020 and december 31, 2019; no shares issued and outstanding as of september 30, 2020 and december 31, 2019 | |||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of june 30, 2020 and december 31, 2019; no shares issued and outstanding as of june 30, 2020 and december 31, 2019 | |||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of march 31, 2020 and december 31, 2019; no shares issued and outstanding as of march 31, 2020 and december 31, 2019 | |||||||||||||||||||||||||
| deferred offering costs | |||||||||||||||||||||||||
| liabilities, redeemable convertible preferred stock and stockholders’ equity | |||||||||||||||||||||||||
| deferred rent | |||||||||||||||||||||||||
| series a redeemable convertible preferred stock, 0.0001 par value, no shares authorized as of december 31, 2019 and 59,433,105 shares authorized as of december 31, 2018; no shares issued and outstanding as of december 31, 2019 and 5,794,727 shares issued and outstanding as of december 31, 2018; liquidation value of 0 as of december 31, 2019 and 47,178 as of december 31, 2018 | |||||||||||||||||||||||||
| series b redeemable convertible preferred stock, 0.0001 par value, no shares authorized as of december 31, 2019 and 75,500,000 shares authorized as of december 31, 2018; no shares issued and outstanding as of december 31, 2019 and 7,345,067 shares issued and outstanding as of december 31, 2018; liquidation value of 0 as of december 31, 2019 and 97,520 as of december 31, 2018 | |||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of december 31, 2019 and no shares authorized as of december 31, 2018; no shares issued and outstanding as of december 31, 2019 and december 31, 2018 | |||||||||||||||||||||||||
| total liabilities, redeemable convertible preferred stock and stockholders’ equity | 113,001,000 | 122,331,000 | 133,358,000 | ||||||||||||||||||||||
| series a redeemable convertible preferred stock, 0.0001 par value, no shares authorized as of september 30, 2019 and 59,433,105 shares authorized as of december 31, 2018; no shares issued and outstanding as of september 30, 2019 and 5,794,727 shares issued and outstanding as of december 31, 2018; liquidation value of 0 as of september 30, 2019 and 47,178 as of december 31, 2018 | |||||||||||||||||||||||||
| series b redeemable convertible preferred stock, 0.0001 par value, no shares authorized as of september 30, 2019 and 75,500,000 shares authorized as of december 31, 2018; no shares issued and outstanding as of september 30, 2019 and 7,345,067 shares issued and outstanding as of december 31, 2018; liquidation value of 0 as of september 30, 2019 and 97,520 as of december 31, 2018 | |||||||||||||||||||||||||
| stockholder’s equity | |||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of september 30, 2019 and no shares authorized as of december 31, 2018; no shares issued and outstanding as of september 30, 2019 and december 31, 2018 | |||||||||||||||||||||||||
| series a redeemable convertible preferred stock, 0.0001 par value, no shares authorized as of june 30, 2019 and 59,433,105 shares authorized as of december 31, 2018; no shares issued and outstanding as of june 30, 2019 and 5,794,727 shares issued and outstanding as of december 31, 2018; liquidation value of 0 as of june 30, 2019 and 47,178 as of december 31, 2018 | |||||||||||||||||||||||||
| series b redeemable convertible preferred stock, 0.0001 par value, no shares authorized as of june 30, 2019 and 75,500,000 shares authorized as of december 31, 2018; no shares issued and outstanding as of june 30, 2019 and 7,345,067 shares issued and outstanding as of december 31, 2018; liquidation value of 0 as of june 30, 2019 and 97,520 as of december 31, 2018 | |||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized as of june 30, 2019 and no shares authorized as of december 31, 2018; no shares issued and outstanding as of june 30, 2019 and december 31, 2018 |
We provide you with 20 years of balance sheets for IDEAYA Biosciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of IDEAYA Biosciences. Explore the full financial landscape of IDEAYA Biosciences stock with our expertly curated balance sheets.
The information provided in this report about IDEAYA Biosciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.